Sun Pharma, SPARC enter into worldwide license agreement for SCD044

29 May 2020 Evaluate

Sun Pharma Advanced Research Company (SPARC) and Sun Pharmaceutical Industries (Sun Pharma) and includes its subsidiaries and/or associate companies have entered into a worldwide license agreement on the development and commercialization of SCD044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other autoimmune disorders. SCD044 is entering phase 2 clinical trials.

Under terms of the license agreement, Sun Pharma will pay SPARC an upfront payment of $20 million. SPARC will also be eligible to receive up to $125 million as milestone payments contingent upon the achievement of clinical, regulatory and sales milestones, as well as tiered royalties on sales. Sun Pharma will be responsible for the development, regulatory filings, manufacturing and commercialization of the product globally.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

Sun Pharma Inds. Share Price

1525.00 7.85 (0.52%)
19-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1525.00
Dr. Reddys Lab 5942.65
Cipla 1345.35
Zydus Lifesciences 925.95
Lupin 1547.05
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.